<DOC>
	<DOCNO>NCT01826448</DOCNO>
	<brief_summary>The purpose research study test safety investigational new drug call PLX3397 use combination Vemurafenib ( Zelboraf™ ) different dose level . Vemurafenib approve United States Food Drug Administration ( FDA ) /European Medicines Agency ( EMA ) treatment specific category unresectable metastatic melanoma .</brief_summary>
	<brief_title>A Phase 1b Open Label , Dose Escalation Study PLX3397 Combination With Vemurafenib V600-mutated BRAF Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Male female ≥18 year old . Patients histologically confirm unresectable Stage III Stage IV metastatic melanoma previously treat selective BRAF inhibitor . Presence BRAF V600 mutation tumor tissue use cobas BRAF mutation assay comparable standard care methodology . Measurable disease per RECIST v. 1.1 criterion . ECOG performance status 0 1 . Radiation therapy within 14 day C1D1 . Investigational drug use within 28 day C1D1 . Patients active CNS lesion exclude ( i.e. , radiographically unstable , symptomatic lesion ) . However , patient treat stereotactic therapy surgery eligible remain without evidence disease progression brain ≥3 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>